Phase Iii Trials

Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech said that the clinical phase III trials of the COVID-19 nasal vaccine have been completed and the company will submit its data with Drugs Controller General of India next month.

Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.

Bharat Biotech today announced that Covaxin, its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III trials.

Biological E has received approval for conducting phase II/III human clinical trial of COVID-19 vaccine candidate Corbevax on children above five years and adolescents, the Department of Biotechnology said today.

Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.

Bharat Biotech has submitted Phase III trial data for the Covaxin coronavirus vaccine to the DCGI (Drug Controller General of India), whose SEC (subject expert committee) is expected to meet later today - likely around noon.

A plea has been moved in the Delhi High Court seeking stay on the phase II/III clinical trials of Covaxin - Bharat Biotech's Covid Vaccine - on 2-18 year olds.

A plea to set aside the permission granted by the Drugs Controller General to Bharat Biotech for conducting phase II/III clinical trial of its Covaxin COVID-19 vaccine on the 2-18 age group was heard by the high court which sought Centre's stand.

The Phase II/III clinical trial of Covaxin, indigenous COVID-19 vaccine, in the 2-18-year-olds will begin in the next 10-12 days and has been approved by the Drugs Controller General Of India, senior NITI Aayog member VK Paul announced Tuesday.

US-based bio-pharmaceutical company HDT Bio Corp on Wednesday announced the start of Phase III trial of its COVID-19 vaccine in India.

Covaxin is 81 per cent effective in preventing Covid and can work against the UK variant of the virus, Bharat Biotech said Wednesday as it revealed a "first interim analysis" of Phase III trial results for a vaccine cleared in January amid concerns over safety and efficacy.

The death of a 45-year-old man in Madhya Pradesh's Bhopal - a volunteer for Phase III trials for Covaxin - was due to "other reasons" and not a severe adverse effect, Dr Anil Dixit, the Dean of the city's People's Medical College, said on Friday

The chairman of Bharat Biotech - whose coronavirus vaccine Covaxin was yesterday given "restricted use in emergency situation in public interest" - hit out today at critics querying the lack of Phase III trial data and others questioning the drug's efficacy

The Drugs Controller General of India (DCGI) has approved conducting phase III trials of the country's first DNA vaccine candidate against COVID-19 being developed by Zydus Cadila, the Department of Biotechnology said on Sunday.

Bharat Biotech has recruited 23,000 volunteers so far for the Phase III clinical trials of its COVID-19 vaccine candidate, ''Covaxin''.

Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech said that the clinical phase III trials of the COVID-19 nasal vaccine have been completed and the company will submit its data with Drugs Controller General of India next month.

Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.

Bharat Biotech today announced that Covaxin, its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III trials.

Biological E has received approval for conducting phase II/III human clinical trial of COVID-19 vaccine candidate Corbevax on children above five years and adolescents, the Department of Biotechnology said today.

Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.

Bharat Biotech has submitted Phase III trial data for the Covaxin coronavirus vaccine to the DCGI (Drug Controller General of India), whose SEC (subject expert committee) is expected to meet later today - likely around noon.

A plea has been moved in the Delhi High Court seeking stay on the phase II/III clinical trials of Covaxin - Bharat Biotech's Covid Vaccine - on 2-18 year olds.

A plea to set aside the permission granted by the Drugs Controller General to Bharat Biotech for conducting phase II/III clinical trial of its Covaxin COVID-19 vaccine on the 2-18 age group was heard by the high court which sought Centre's stand.

The Phase II/III clinical trial of Covaxin, indigenous COVID-19 vaccine, in the 2-18-year-olds will begin in the next 10-12 days and has been approved by the Drugs Controller General Of India, senior NITI Aayog member VK Paul announced Tuesday.

US-based bio-pharmaceutical company HDT Bio Corp on Wednesday announced the start of Phase III trial of its COVID-19 vaccine in India.

Covaxin is 81 per cent effective in preventing Covid and can work against the UK variant of the virus, Bharat Biotech said Wednesday as it revealed a "first interim analysis" of Phase III trial results for a vaccine cleared in January amid concerns over safety and efficacy.

The death of a 45-year-old man in Madhya Pradesh's Bhopal - a volunteer for Phase III trials for Covaxin - was due to "other reasons" and not a severe adverse effect, Dr Anil Dixit, the Dean of the city's People's Medical College, said on Friday

The chairman of Bharat Biotech - whose coronavirus vaccine Covaxin was yesterday given "restricted use in emergency situation in public interest" - hit out today at critics querying the lack of Phase III trial data and others questioning the drug's efficacy

The Drugs Controller General of India (DCGI) has approved conducting phase III trials of the country's first DNA vaccine candidate against COVID-19 being developed by Zydus Cadila, the Department of Biotechnology said on Sunday.

Bharat Biotech has recruited 23,000 volunteers so far for the Phase III clinical trials of its COVID-19 vaccine candidate, ''Covaxin''.